What this guide is, and is not
This page explains the legal framework that applies to peptides sold in the United Kingdom as chemicals for laboratory research. It is written by a scientific editor, not a solicitor, and it is general information rather than legal advice. The law and enforcement priorities change, and the facts of a particular case matter; anyone who needs to know how the rules apply to their own situation should take advice from a qualified lawyer or ask the regulator directly.
The framework is less mysterious than the volume of confident misinformation online suggests. Most of it turns on one question: is the product a medicine?
What a medicinal product is
The governing instrument is the Human Medicines Regulations 2012 (SI 2012/1916), which consolidated UK medicines law and is administered by the Medicines and Healthcare products Regulatory Agency (MHRA). Regulation 2 defines a "medicinal product" in two limbs. The first is any substance or combination of substances "presented as having properties of preventing or treating disease in human beings". The second is any substance that may be used by or administered to human beings with a view to restoring, correcting or modifying a physiological function by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis [1].
These are the presentation limb and the function limb, and a product falls within the definition if it satisfies either. The MHRA's guidance on borderline products explains how it applies them: it looks at explicit and implicit claims, the pharmacological properties of the ingredients, the primary intended purpose of the product and how consumers would actually use it, whether comparable licensed products exist, and how the product is presented to the public through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews [2]. "Disease" is read broadly to include any injury, ailment or adverse condition of body or mind.
Once something is a medicinal product, the rest of the Regulations follow. Regulation 46 provides that a person may not sell or supply, or offer to sell or supply, a medicinal product that has no marketing authorisation, and regulation 47 makes a breach an offence punishable on indictment by a fine, imprisonment of up to two years, or both [1]. Where the product is a prescription-only medicine, regulation 214 adds that it may not be sold or supplied except in accordance with a prescription given by an appropriate practitioner [1].
Why a research chemical is not placed on the market as a medicine
A peptide supplied as a chemical for in-vitro research is not, on its face, a medicinal product. It is not presented as preventing or treating disease: the labelling says research use only, the product page describes chemical identity and analytical data rather than effects in people, and the terms of sale exclude human and veterinary use. It is not sold with a view to administration to human beings. On the MHRA's own criteria it is therefore not placed on the market as a medicine, and regulations 46 and 214 are not engaged.
Two qualifications are essential.
First, the presentation limb is about the whole picture, not the label alone. The MHRA says in terms that it looks at websites, social media and customer reviews. A product labelled "not for human consumption" but marketed alongside dosing schedules, before-and-after photographs, user testimonials or "protocols" is being presented for human use, and the disclaimer does not change that. This is why a responsible seller publishes no dosing or administration content and hosts no reviews describing personal use.
Second, the function limb is about the substance. Semaglutide, tirzepatide and liraglutide are the active ingredients of licensed prescription-only medicines in the UK, and the MHRA's guidance treats the existence of a comparable licensed product as a relevant factor. Supplying such a substance to a person for them to take, with or without a research label, is supplying an unauthorised medicine and a prescription-only medicine without a prescription, and it is an offence [1]. The legal status of the vial depends on what it is for and how it is presented, not on the chemistry in it.
The practical consequence is a strict division. Research-grade peptide sold to a laboratory, for use in an assay, with analytical documentation and without medicinal claims, sits outside the medicines framework. The same vial sold to an individual for self-administration sits inside it, and the seller is the one committing the offence.
The Psychoactive Substances Act 2016
The Psychoactive Substances Act 2016 is sometimes raised because "research chemicals" and "legal highs" have become tangled in public discussion. The Act applies to a "psychoactive substance", defined in section 2 as any substance capable of producing a psychoactive effect in a person who consumes it, and not an exempted substance. A substance produces a psychoactive effect if, "by stimulating or depressing the person's central nervous system, it affects the person's mental functioning or emotional state" [3].
Peptides of the kind sold here do not act by stimulating or depressing the central nervous system in that sense. Incretin analogues act on GIP and GLP-1 receptors; BPC-157 and TB-500 are studied for effects on tissue repair; GHK-Cu is a copper-binding tripeptide; growth-hormone secretagogues act on the ghrelin receptor. None is consumed for a psychoactive effect, and the Act in any case exempts medicinal products. It is simply not the relevant statute.
The Misuse of Drugs Act 1971
The Misuse of Drugs Act 1971 controls the substances listed in Schedule 2 in Classes A, B and C, with possession, supply and production offences attached.
Anabolic and androgenic steroids are Class C under Part III of Schedule 2, and so are a small group of non-steroidal substances listed alongside them: clenbuterol, chorionic gonadotrophin (HCG), non-human chorionic gonadotrophin, and the growth-hormone products somatotropin, somatrem and somatropin [4]. The inclusion of HCG and the somatropin group means that, contrary to what is often said, some peptide hormones are controlled drugs in the UK. For the Class C substances in that paragraph, possession for personal use is generally not an offence, but supply, and possession with intent to supply, are.
None of the peptides sold by BuyUK Peptides is listed in Schedule 2. Growth-hormone secretagogues such as ipamorelin and CJC-1295 are not growth hormone and are not named; incretin analogues, BPC-157, TB-500 and GHK-Cu do not appear in any class. We do not sell growth hormone, HCG or any steroid, and we check the schedules when a new compound is added. The current consolidated text is on legislation.gov.uk [4].
Sport: the WADA Prohibited List and UK Anti-Doping
Anti-doping rules are not law, but they bind anyone who competes under a code-compliant governing body. UK Anti-Doping (UKAD) applies the World Anti-Doping Code in the UK, publishes the WADA Prohibited List and directs athletes to the Global DRO database to check medications [6].
The 2026 Prohibited List, in force from 1 January 2026, is explicit about the peptides that concern us [5].
- BPC-157 is named under S0, non-approved substances: the class covering any pharmacological substance not addressed elsewhere on the List and without current approval by any governmental regulatory health authority for human therapeutic use. The List says the class includes "but is not limited to" BPC-157, and S0 substances are prohibited at all times, in and out of competition [5].
- Thymosin-β4 and its derivatives, "e.g. TB-500", are named under S2.3, growth factors and growth factor modulators, prohibited at all times [5].
- Growth-hormone secretagogues and releasing peptides are listed under S2.2.4 (growth hormone releasing factors), which names ipamorelin, CJC-1295, sermorelin, tesamorelin and the GHRP series [5].
- GLP-1 receptor agonists (semaglutide, tirzepatide and related compounds) do not appear anywhere on the 2026 List, and nor does GHK-Cu [5]. The S4 section on hormone and metabolic modulators covers insulins and insulin-mimetics, but not incretin analogues.
Two points follow. An athlete subject to testing who handles BPC-157 or TB-500 in any capacity should understand that strict liability means the presence of the substance in a sample is a violation regardless of intent. And S0 is deliberately open-ended: a research peptide not named on the List is still prohibited for athletes if it has no regulatory approval for human use anywhere, which describes most of any research-chemical catalogue.
Cosmetics: GHK-Cu as a cosmetic ingredient
GHK-Cu occupies an unusual position because the same tripeptide-copper complex is a widely used ingredient in finished cosmetic products. Cosmetics in Great Britain are governed by Regulation (EC) No 1223/2009 as retained and amended on EU exit, enforced by the Office for Product Safety and Standards (OPSS). A finished cosmetic product placed on the GB market requires a UK-established Responsible Person, a product safety report by a qualified assessor, notification through the Submit Cosmetic Product Notifications service, a product information file kept for ten years, and compliant labelling [7].
Those obligations attach to the finished cosmetic and its Responsible Person, not to a raw ingredient. Research-grade GHK-Cu sold as a chemical is neither a cosmetic nor a medicine. A buyer who incorporates it into a cosmetic for sale takes on the full set of cosmetics obligations, and a cosmetic that makes medicinal claims (treating a skin disease, for instance) crosses back into the medicines framework under the presentation limb.
Chemicals law: UK REACH, GB CLP and safety data sheets
Because a research peptide is a chemical, the chemicals regime applies in the ordinary way. UK REACH, administered by the Health and Safety Executive, governs the registration, evaluation, authorisation and restriction of chemicals in Great Britain; research peptides are traded in quantities far below the registration thresholds, but the duty to communicate hazard information does not depend on tonnage. The GB CLP Regulation requires substances placed on the market to be classified, labelled and packaged under the Globally Harmonised System, with HSE as the GB CLP agency [8].
A safety data sheet must be provided where a chemical is hazardous and is supplied for use at work, and where a product not itself classified as hazardous contains small amounts of a hazardous substance [8]. Most peptides are not classified as hazardous, but a responsible supplier provides an SDS in the standard sixteen-section format for each compound anyway, so that a laboratory can complete its COSHH assessment.
What a responsible seller does
Taking the framework together, a research-chemical seller operating within the law does the following, and a buyer can judge a supplier by whether it does.
- Sells to adults only. Purchasers must confirm they are 18 or over.
- Sells under research-use terms. The Terms of Sale state that products are for in-vitro laboratory research, are not for human or veterinary use, and are not medicines, cosmetics or food. The purchaser accepts those terms as a condition of sale.
- Makes no medicinal claims and publishes no dosing content. Product pages describe identity, structure, published pharmacology and analytical data. They do not describe effects in people, recommend doses or routes, or host testimonials. This is what keeps the product outside the presentation limb, and it is the point on which many sellers fail.
- Publishes independent certificates of analysis. Every batch is tested by a third-party laboratory for purity and identity, and the certificate is in the certificate register. That the product is the chemical it claims to be is a matter of consumer law as much as of science.
- Provides safety data sheets for each compound.
- Is identifiable. The trading company is registered at Companies House, with its registered number, address and directors on the about page. A seller that cannot be identified cannot be held to its terms or its certificates.
- Does not sell controlled drugs, and checks Schedule 2 of the 1971 Act when adding a compound.
- Declines orders where the circumstances indicate that the product is intended for human use.
What the buyer is responsible for
The seller's obligations end at the point of supply. From there, responsibility passes to the purchaser, and the terms make that explicit.
A buyer is responsible for using the material only for the research purpose for which it was supplied, in a setting appropriate to that purpose; for complying with the rules of any institution, employer or ethics body that governs their work, and with COSHH where the material is handled at work; for their own anti-doping compliance if they are an athlete; and, if they resell or incorporate a compound into another product, for the regulatory obligations of that product under medicines, cosmetics or chemicals law. A buyer who uses a research chemical in a way the terms prohibit is in breach of contract and may be exposing themselves to the medicines offences described above.
None of this is unusual. It is the same allocation of responsibility that applies to any chemical sold to a laboratory, from a solvent to a reference standard. What is unusual about peptides is only the gap between what the research market sells and what some of its customers want it to be, and the law is clear about which side of that gap a seller must stay on.
References
- The Human Medicines Regulations 2012, SI 2012/1916: regulation 2 (definition of "medicinal product"); regulation 46 (requirement for authorisation); regulation 47 (offence and penalties); regulation 214 (sale and supply of prescription only medicines). legislation.gov.uk.
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. GOV.UK guidance. gov.uk. Accessed October 2026.
- Psychoactive Substances Act 2016, c. 2, section 2 (meaning of "psychoactive substance"). legislation.gov.uk.
- Misuse of Drugs Act 1971, c. 38, Schedule 2, Part III (Class C drugs). legislation.gov.uk.
- World Anti-Doping Agency. The 2026 Prohibited List: World Anti-Doping Code International Standard. In force 1 January 2026. wada-ama.org.
- UK Anti-Doping. The Prohibited List and Global DRO. ukad.org.uk. Accessed October 2026.
- Office for Product Safety and Standards. Making cosmetic products available to consumers in Great Britain. GOV.UK guidance. gov.uk. Accessed October 2026.
- Health and Safety Executive. UK REACH; The GB CLP Regulation; Safety data sheets. hse.gov.uk. Accessed October 2026.
This monograph summarises the published literature for laboratory researchers. It is not medical advice, and nothing on this site is for human or veterinary use.